Isolation of Human CD138+ Microparticles from the Plasma of Patients with Multiple Myeloma

Neoplasia (United States)

Volumn 18, Issue 1, 2016, Pages 25-32

  Krishnan, Sabna Rajeev ^a   Luk, Frederick ^a   Brown, Ross D ^b   Suen, Hayley ^b   Kwan, Yiulam ^c   Bebawy, Mary ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; SYNDECAN 1; THALIDOMIDE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER INFILTRATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CELL INTERACTION; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MEMBRANE MICROPARTICLE; MEMBRANE VESICLE; MULTIPLE MYELOMA; PARTICLE SIZE; PATIENT MONITORING; PLASMA CELL; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; THROMBOSIS; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; BIOPSY; BONE MARROW; METABOLISM; MIDDLE AGED; PATHOLOGY; ULTRASTRUCTURE;

BIOPSY; BONE MARROW; CELL-DERIVED MICROPARTICLES; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; SYNDECAN-1;

EID: 84963959674     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.11.011     Document Type: Article

References (38)

1. Turesson I, Velez R, Kristinsson SY, Landgren O Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010, 28(5):830-834.
2. Lonial S, Mitsiades CS, Richardson PG Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011, 17(6):1264-1277.
3. Paino T, Paiva B, Sayagues JM, Mota I, Carvalheiro T, Corchete LA, et al. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia 2014, 29(5):1186-1194.
4. Morel O, Toti F, Hugel B, Freyssinet JM Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004, 11(3):156-164.
5. Hugel B Membrane microparticles: two sides of the coin. Physiology 2005, 20(1):22-27.
6. Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 2009, 23(9):1643-1649.
7. Gelderman MP, Simak J Flow cytometric analysis of cell membrane. Microparticles 2008, 484:79-93.
8. Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, Woywodt A, et al. Diagnostic role of endothelial microparticles in vasculitis. Rheumatology 2008, 47(12):1820-1825.
9. Tramontano AF, Lyubarova R, Tsiakos J, Palaia T, Deleon JR, Ragolia L Circulating endothelial microparticles in diabetes mellitus. Mediators Inflamm 2010, 2010:250476.
10. Coppola A, Tufano A, Di Capua M, Franchini M Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 2011, 37(8):929-945.
11. Simak J, Gelderman MP Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006, 20(1):1-26.
12. Harding C, Heuser J, Stahl P Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983, 97(2):329-339.
13. Chilosi M, Adami F, Lestani M, Montagna L, Cimarosto L, Semenzato G, et al. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 1999, 12(12):1101-1106.
14. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999, 68:729-777.
15. Gotte M Syndecans in inflammation. FASEB J 2003, 17(6):575-591.
16. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009, 30(3):397-407.
17. O'Connell FP, Pinkus JL, Pinkus GS CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol 2004, 121(2):254-263.
18. Rawstron AC Immunophenotyping of plasma cells. Curr Protoc Cytom 2006, [Chapter 6: Unit 6.23].
19. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20(9):1467-1473.
20. Yuana Y, Bertina RM, Osanto S Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011, 105(3):396-408.
21. Lacroix R, Robert S, Poncelet P, Dignat-George F Overcoming limitations of microparticle measurement by flow cytometry. Semin Thromb Hemost 2010, 36(8):807-818.
22. Su J, Zhang L, Zhang W, Choi DS, Wen J, Jiang B, et al. Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling. PLoS One 2014, 9(1):e85059.
23. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103(6):2332-2336.
24. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23(2):215-224.
25. Tate J, Bazeley S, Sykes S, Mollee P Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev 2009, 30(3):131-140.
26. Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R, et al. Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J 2011, 26(1):420-429.
27. Dimopoulos MA, Terpos E Multiple myeloma. Ann Oncol 2010, 21(suppl 7):vii143-vii150.
28. Benameur T, Chappard D, Fioleau E, Andriantsitohaina R, Martinez MC, Clere N, et al. Plasma cells release membrane microparticles in a mouse model of multiple myeloma. Micron 2013, 54-55:75-81.
29. Khotskaya YB, Dai Y, Ritchie JP, MacLeod V, Yang Y, Zinn K, et al. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem 2009, 284(38):26085-26095.
30. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 2001, 14(10):1052-1058.
31. Reid S, Yang S, Brown R, Kabani K, Aklilu E, Ho PJ, et al. Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. Int J Lab Hematol 2010, 32(6 Pt 1):e190-e196.
32. Jaiswal R, Luk F, Dalla PV, Grau GE, Bebawy M Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS One 2013, 8(4):e61515.
33. Pokharel D, Padula MP, Lu JF, Tacchi JL, Luk F, Djordjevic SP, et al. Proteome analysis of multidrug-resistant, breast cancer-derived microparticles. J Extracell Vesicles 2014, 3.
34. Jaiswal R, Gong J, Sambasivam S, Combes V, Mathys JM, Davey R, et al. Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J 2012, 26(1):420-429.
35. Lu JF, Luk F, Gong J, Jaiswal R, Grau GE, Bebawy M Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways. Pharmacol Res 2013, 76:77-83.
36. Gertz MA, Buadi FK Plasma cell leukemia. Haematologica 2010, 95(5):705-707.
37. Gyorgy B, Szabo TG, Turiak L, Wright M, Herczeg P, Ledeczi Z, et al. Improved flow cytometric assessment reveals distinct microvesicle (cell-derived microparticle) signatures in joint diseases. PLoS One 2012, 7(11):e49726.
38. Nadalin MR, Fregnani ER, Silva-Sousa YT, Perez DE Syndecan-1 (CD138) and Ki-67 expression in odontogenic cystic lesions. Braz Dent J 2011, 22(3):223-229.